Australia's most trusted
source of pharma news
Posted 1 May 2024 AM
CSL Vifor has proposed a marketing campaign in the European Union to address concerns of possible anticompetitive disparagement of a competitor's product.
The European Commission opened an antitrust investigation into Vifor in June 2022, right when it was in the process of being acquired by CSL. Vifor's intravenous iron treatment, Ferinject, was dominant in several national markets including Austria, Finland, Germany, Ireland, Portugal, Romania, Spain, Sweden, and The Netherlands.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.